

ENDOCYTE INC  
Form 8-K  
June 21, 2011

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

June 15, 2011

Endocyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-35050

35-1969-140

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

3000 Kent Avenue, Suite A1-100, West  
Lafayette, Indiana

47906

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

765-463-7175

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 15, 2011, Endocyte, Inc. (the "Company") announced that it had appointed Binh Nguyen, M.D., Ph.D., as Vice President of Clinical Affairs, succeeding to the responsibilities previously performed by Richard Messmann, M.D., one of the Company's "named executive officers". Dr. Messmann's employment with the Company is expected to terminate effective July 22, 2011, and will entitle him, under his Change in Control and Severance Agreement, to receive the severance benefits applicable to a termination of employment without cause or by the executive with good reason occurring prior to a change in control transaction.

A copy of the Company's press release announcing these events is attached as Exhibit 99.1 to this report and the information in the press release is incorporated by reference into this report.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit 99.1 Press release dated June 15, 2011

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Endocyte, Inc.

*June 21, 2011*

By: */s/ Michael A. Sherman*

---

*Name: Michael A. Sherman  
Title: Chief Financial Officer*

---

Edgar Filing: ENDOCYTE INC - Form 8-K

**Top of the Form**

Exhibit Index

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press release dated June 15, 2011